Beckman Coulter Receives the US FDA’s Clearance for Access MeMed BV Assay to Differentiate Bacterial vs Viral Infections

Shots: The US FDA has cleared Beckman Coulter‘s Access MeMed BV assay, developed in collaboration with MeMed, a rapid host-response blood test to help differentiate bacterial from viral infections in adult & pediatric pts (aged ≥90 days) The assay runs on the DxI 9000 & Access 2 immunoassay analyzers already installed in hospital labs, with results available in as little as 15 mins on the DxI 9000, without requiring new instruments or workflow changes Published health-economic modeling in community-acquired pneumonia estimated ~1,129 fewer antibiotic days/1,000 pts when MeMed BV was added to the diagnostic SOC Ref: PR Newswire  |   Image: Beckman Coulter  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Beckman Coulter Receives the US FDA’s Clearance for Access MeMed BV Assay to Differentiate Bacterial vs Viral Infections appeared first on PharmaShots.